reference/20881942

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20881942

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial
endingPage	194
issn	1527-7755 0732-183X
issueIdentifier	2
pageRange	189-194
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	189
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d4507fc7d529f1e9e60547855348d4d9
bibliographicCitation	Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol. 2015 Jan 10;33(2):189–94. PMID: 25452446; PMCID: PMC4890680.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc17123ecee264a649d5f4ed7778a360 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c81819c8c559f32b7d547278a300a9e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b68574e08c7e89099346dabf0c62e8be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_17c297d856458082c29e59c2bb53c8f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_722eb783c7b2ff58d5cbc9378ff13e23 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_17103506df543c638f1a40a858076a9e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dd7fb0f6125365e4bdba4d5646dd6989 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b317af9b460f15ff4b3170184bcbdfb1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9948c66a9e877f9fd17d494ee8422132 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ccdbcaf3a4c369a3235357a60d6ae906 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2afc04db028aab9a6f22ed46994a55ea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_014e9df353f8e7424225715d9dec4fe4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_30d915ef59f5c6bbe9a2ee9b5e4aa4a1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef4f76463f52de45c2715279510b250f
date	2015-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1200/jco.2014.55.5789 https://pubmed.ncbi.nlm.nih.gov/PMC4890680 https://pubmed.ncbi.nlm.nih.gov/25452446
isPartOf	https://portal.issn.org/resource/ISSN/0732-183X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023 https://portal.issn.org/resource/ISSN/1527-7755
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer
discusses	http://id.nlm.nih.gov/mesh/M0258705 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0480958 http://id.nlm.nih.gov/mesh/M0168144 http://id.nlm.nih.gov/mesh/M0018276 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0020790 http://id.nlm.nih.gov/mesh/M0022149 http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M0017805 http://id.nlm.nih.gov/mesh/M0503331 http://id.nlm.nih.gov/mesh/M0009376
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D011453Q000652 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D014408Q000652
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D013449Q000008 http://id.nlm.nih.gov/mesh/D002289Q000473 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008175Q000652 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D051546Q000378 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D011758Q000008 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D002289Q000652 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D005971Q000008 http://id.nlm.nih.gov/mesh/D018579 http://id.nlm.nih.gov/mesh/D011758Q000009 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D000077143 http://id.nlm.nih.gov/mesh/D000068437 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D013449Q000009 http://id.nlm.nih.gov/mesh/D043823Q000008 http://id.nlm.nih.gov/mesh/D006147Q000031
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71684390 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280360 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID161468 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9820073 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_25e7482d087cb6429609f07a507aa159 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875

Total number of triples: 92.